Targeted
Immuno-Oncology Platform

Targeted Immuno-Oncology Platform

Therapy Indication Partners Discovery Pre-Clinical Phase I Phase II
https://eagfwc.org/men/cytotec-used-for-induction/100/ viagra bula infarmed go to link rimedi naturali effetto viagra how to write a conclusion for a essay internet argumentative essay how to by cytotec worldwide https://abt.edu/bestsellers/cialis-tachyphylaxis/22/ how do i set up voicemail on my iphone 8 https://shepherdstown.info/conclusion/custom-college-essay-writing-service/17/ how to write articles of organization https://tffa.org/businessplan/essay-sample-exam/70/ study writing english online invasive species case study http://windmillharbourmarina.org/cialis-daily-use-user-reviews/ whi is viagra so expensive in the usa seroquel and urine drug screens kamagra comprar portugal https://pinnacle.berea.edu/where/side-effects-drug-crestor/50/ connective words list essay o pioneers essay topics see doxycycline tablets what are they for books opinion essay essays on radiation protection buy cilias without prescription acheter cialis en suisse enter position essay example viagra oesterreich https://zsjnm.huc.edu/analytical/dissertation-questions-on-brexit/2/ ACT-901
(AFP + paclitaxel)
Targeted Immuno-Oncology
Solid and liquid tumors
Collaboration University Health Network
 
ACT-902
(AFP + thapsigargin)
Targeted Immuno-Oncology
Solid and liquid tumors
Collaboration University Health Network
 
ACT-903
(AFP + linker + maytansine)
Targeted Immuno-Oncology
Solid and liquid tumors
Collaboration Abzena
 

Lead Assets

ACT-901 (AFP + paclitaxel)

  • Paclitaxel is a widely used generic chemotherapy
  • ACT-901 combines highly targeted transporter protein AFP with a paclitaxel payload

ACT-902 (AFP + thapsigargin)

  • Thapsigargin is a potent generic chemotherapy drug equally effective against aggressive and slow growing tumors
  • ACT-902 combines highly targeted transporter protein AFP with a thapsigargin payload

ACT-903 (AFP + linker + maytansine)

  • Maytansine is a potent microtubule-targeted chemotherapy drug that induces mitotic arrest and kills tumor cells
  • ACT-903 combines highly targeted transporter protein AFP with a maytansine payload using cleavable linker

Targeted Immuno-Oncology

Alpha Fetoprotein (AFP)

  • AFP a shuttle protein that targets AFP receptors on cancer cells
  • Majority of solid and liquid cancer cells (>80%) have AFP receptors
  • Healthy cells do not have AFP receptors
  • Payload is delivered selectively to cancer cells

Preparation of ACT-901 (Taxol Solubilization)

Benefits

  • Formulation combining two well-known compounds
  • Currently in development for ovarian cancer / testicular germ cell tumors – Orphan Drug / Breakthrough Therapy
  • Will expand to other major indications
  • Overcomes chemotherapy drug resistance as delivery bypasses membrane pumps
  • AFP is non-immunogenic in humans - demonstrated safety in over 300 patients (as safe as placebo)
  • Frequency of treatment driven by efficacy, not toxicity avoidance
  • Treatment expected to minimize pain, suffering and healthcare cost

Target Product Profile

  • Significantly less toxicity than targeted and non-targeted chemotherapy
  • Improved efficacy compared with chemotherapy
  • Not necessary to preselect patients for expression of the AFP receptor, because receptors are expressed in most cancers (solid and liquid), but are absent in normal tissues